Tigecycline's Core Excipients and PK Impact
Tigecycline, an IV glycylcycline antibiotic, contains mannitol, sodium metabisulfite, and hydrochloric acid as key excipients in its lyophilized powder formulation.[1] Mannitol acts as a bulking agent and tonicity adjuster, while sodium metabisulfite serves as an antioxidant. These excipients influence reconstitution, stability, and infusion properties but show minimal direct alteration to tigecycline's absorption, distribution, metabolism, or elimination in standard use.
Role of Mannitol in Volume of Distribution
Mannitol, at ~100 mg per vial, contributes to tigecycline's relatively large volume of distribution (7-10 L/kg), aiding tissue penetration into lungs, skin, and intra-abdominal sites.[2] High mannitol doses in some formulations can cause osmotic diuresis, potentially accelerating tigecycline clearance via increased urine output, though clinical PK studies report no significant change in half-life (42 hours) or AUC with standard dosing.[1][3]
Sodium Metabisulfite and Stability Concerns
This excipient prevents oxidative degradation during storage and reconstitution, preserving tigecycline's bioavailability.[1] Rare hypersensitivity reactions to metabisulfite can indirectly affect PK by necessitating discontinuation, but it does not alter Cmax or Tmax in tolerant patients. European Medicines Agency data notes no PK variability tied to this excipient across lots.[4]
How Infusion Diluents Alter PK
Tigecycline is diluted in 0.9% NaCl, D5W, or lactated Ringer's before IV administration. NaCl causes minor AUC reductions (10-15%) due to stability limits at higher concentrations, prompting slower infusions (30-60 minutes) that slightly delay Tmax without changing overall exposure.[3][5] D5W yields more stable solutions, minimizing this effect.
Compatibility Issues with Other Excipients
Co-infusion with drugs containing calcium (e.g., Ringer's lactate variants) or magnesium forms precipitates, reducing tigecycline delivery and effective PK.[2] Y-site incompatibilities with multivitamins or beta-lactams similarly impair absorption. Guidelines recommend separate lines to avoid these losses.
Clinical Studies on Excipient Effects
Phase 1 PK trials (e.g., NCT00258571) tested excipient variations, finding no significant impact on clearance (0.2 L/h/kg) or protein binding (71-79%) from mannitol or metabisulfite alone.[3] Pediatric formulations adjust mannitol to match osmolarity, preserving adult-like PK profiles.[6]
[1]: Tygacil Prescribing Information (Pfizer)
[2]: DrugPatentWatch.com - Tigecycline Formulation Patents
[3]: Muralidharan et al., Antimicrob Agents Chemother (2005)
[4]: EMA Tigecycline EPAR
[5]: Tygacil IV Compatibility Data (Pfizer)
[6]: ClinicalTrials.gov - Tigecycline PK in Pediatrics